Biotron Ltd - Company Profile
Powered by 
All the sales intelligence you need on Biotron Ltd in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Biotron Ltd fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Biotron Ltd.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Business Description
Biotron Ltd (Biotron) specializes in designing and developing antiviral drugs targeting viroporins, virus-encoded proteins critical to viral pathogenesis. Viroporins are involved in viral processes that allow viruses to evade host immune responses and sustain ongoing infection. Biotron’s proprietary library of compounds targets viroporins across a broad range of viruses, offering potential therapeutic solutions for serious viral infections in humans and other hosts.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
R&D Overview
The company's R&D activities focus on the development of a new class of antiviral therapies, with its lead compound, BIT225, in Phase 2 development for treating HIV-1 and Hepatitis C virus infections. BIT225 shows potential in inhibiting HIV-1 replication in macrophage reservoir cells, which could help eradicate HIV-1 when used with other anti-retroviral compounds. The company also has a robust preclinical pipeline targeting a broad range of viral diseases, including efforts to develop an antiviral drug for SARS-CoV-2. BIT225 has demonstrated efficacy against SARS-CoV-2 in early-stage research, accelerating the clinical and regulatory pathway for the company's COVID-19 program. Biotron is developing small molecule therapeutics targeting viral-encoded viroporin proteins, addressing both established and emerging viral diseases. In FY2025, the company spent AUD0.5 million on its R&D activities.
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer